Literature DB >> 33999386

Hans Joachim Scherer: an under-recognized pioneer of glioma research in Belgium.

Gilles Reuter1,2, Arnaud Lombard3, Eric Suero Molina4, Felix Scholtes3,5, Elettra Bianchi6.   

Abstract

Hans Joachim Scherer (1906-1946) was a German pathologist who fled Germany to Belgium to work on glioma genesis, growth and progression. Despite being seldom cited, and due to the contributions discussed in this article, Hans Joachim Scherer, can be considered a founding father of contemporary neuropathology and glioma research. We discuss Scherer's achievements in glioma classification, glomerular structures of glioma, primary and secondary glioblastoma, glioma growth patterns, non-resectability of glioma, pseudopalisadic necrosis and the late occurrence of symptoms in glioma.
© 2021. Belgian Neurological Society.

Entities:  

Keywords:  Glioblastoma; Glioma; Scherer’s figures

Mesh：

Year:  2021        PMID： 33999386     DOI： 10.1007/s13760-021-01708-z

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN： 0300-9009            Impact factor:   2.396


  19 in total

Review 1.  Percival Bailey and the classification of brain tumors.

Authors:  Sherise Ferguson; Maciej S Lesniak
Journal:  Neurosurg Focus       Date:  2005-04-15       Impact factor: 4.047

2.  Some comments on the paper: Hans-Joachim Scherer (1906-1945), pioneer in glioma research.

Authors:  Marc Scherer
Journal:  Brain Pathol       Date:  2013-07       Impact factor: 6.508

3.  Diagnosis of Intracranial Tumors by Supravital Technique.

Authors:  L Eisenhardt; H Cushing
Journal:  Am J Pathol       Date:  1930-09       Impact factor: 4.307

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

Review 6.  The definition of primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

7.  IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.

Authors:  Sumihito Nobusawa; Takuya Watanabe; Paul Kleihues; Hiroko Ohgaki
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

8.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.

Authors:  M Hermanson; K Funa; M Hartman; L Claesson-Welsh; C H Heldin; B Westermark; M Nistér
Journal:  Cancer Res       Date:  1992-06-01       Impact factor: 12.701

9.  Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms.

Authors:  K H Plate; G Breier; H A Weich; H D Mennel; W Risau
Journal:  Int J Cancer       Date:  1994-11-15       Impact factor: 7.396

Review 10.  Hans Joachim Scherer and His Impact on the Diagnostic, Clinical, and Modern Research Aspects of Glial Tumors.

Authors:  George S Stoyanov; Lilyana Petkova; Deyan L Dzhenkov
Journal:  Cureus       Date:  2019-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.